Notice of Intent to Publish a Funding Opportunity Announcement for Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
Notice Number:

Key Dates

Release Date:
August 02, 2022
Estimated Publication Date of Funding Opportunity Announcement:
November 30, 2022
First Estimated Application Due Date:
February 17, 2023
Earliest Estimated Award Date:
October 20, 2023
Earliest Estimated Start Date:
October 27, 2023
Related Announcements


Issued by

National Cancer Institute (NCI)


The National Cancer Institute (NCI) intends to publish a Funding Opportunity Announcement (FOA) to solicit applications that support the development and testing of cancer-related interventions using a pragmatic trial design.

This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations.

The FOA is expected to be published in Fall 2022 with an expected first application due date in February 2023.

The intended FOA will utilize the UG3/UH3 mechanism.

Research Initiative Details

The National Cancer Institute (NCI) intends to publish a Funding Opportunity Announcement (FOA) to invite applications on pragmatic trials across the cancer control continuum. The overarching goal of this FOA is to support the development of a more robust, representative, and diverse collection of evidence-based cancer-related interventions.

For the purposes of this announcement, pragmatic trials are conceptualized as trials that are intentionally designed to closely reflect the population(s) that would benefit from the intervention, and context(s) in which the intervention would be delivered, pending supportive trial outcome data. Examples of relevant pragmatic trial design elements for consideration include eligibility criteria, selection of primary outcome(s) that are important to patients, providers, and partners, data collection approaches and measures, and contextual aspects of the setting(s) in which the trial will take place, among others.

Applications are expected to propose a pragmatic trial to test the effect of a cancer-related intervention(s) on a cancer-related outcome(s) across the cancer control continuum. Proposed interventions may be single and/or multilevel and may focus on individuals, providers, healthcare systems, and/or public health settings, among others. Interventions may focus on populations that are underserved, from racial and ethnic minority groups, and under-resourced communities and healthcare delivery systems, among others. Examples of cancer-related outcomes include (but are not limited to) health status, health behaviors, quality of care, and delivery of evidence-based interventions in healthcare and public health settings. Applications that propose to develop and test cancer-directed therapies, imaging, diagnostics, or devices, or do not include purposeful consideration and inclusion of pragmatic trial design elements, would be considered non-responsive to this announcement.

Funding Information
Estimated Total Funding


Expected Number of Awards
Estimated Award Ceiling

The maximum award for the UG3 phase is $500,000 direct costs per year for up to 2 years. The maximum award for the UH3 phase is $750,000 direct costs per year for up to 4 years.

Primary Assistance Listing Number(s)


Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Regional Organization

Applications are not being solicited at this time. 


Please direct all inquiries to:

Wynne E. Norton, PhD

National Cancer Institute (NCI)